Introduction
In multiple myeloma (MM), high-dose therapy with autologous stem cell transplantation is now extensively used, and results in better remission and survival rates compared with standard multiagent chemotherapy. 1 However, autologous transplantation does not eradicate the disease 2 with recurrence within 3-5 years still occurring in the majority of cases, although data compatible with cure are reported after tandem autografts in favorable patients who remain 47 years in remission. 3 Molecular biology studies show that disappearance of the MM clone occurs only occasionally and transiently after autologous transplantation. 4 The experience with syngeneic transplantation, where the graft does not contain neoplastic cells, indirectly confirms the view that in autologous transplantation myeloma cells -either surviving treatment or reinfused with the graft -are at the origin of relapse. 5 Allogeneic transplantation has been employed much less than autologous. This is due mainly to its toxic effects, resulting in infectious complications and severe GVHD. [6] [7] [8] In a large matched-pair analysis, 9 allogeneic transplantation proved inferior to autologous in terms of survival. In fact, despite the lower relapse rate, allogeneic transplantation retained a much higher transplant-related mortality (TRM). Reduction of transplant toxicity is therefore a key problem in patients with MM, and different paths are being explored. It was in an effort to decrease TRM that we developed a program for MM introducing the use of peripheral blood stem cells (PBSC) instead of bone marrow. Initially, we considered a possible advantage of PBSC in terms of transplant safety, as already shown in the autologous setting. 10 Initial results soon appeared promising, 11 and we extended the experience to a larger number of patients. Here, we present the results on a series of 30 patients who now have a median follow-up of 3 years.
Patients and methods

Patient and donor characteristics
Transplants were undertaken between 1995 and 2001. MM patients were admitted to the program of allogeneic PBSC transplantation provided they were o60-year-old, and had a fully-matched HLA (A, B, C, DR identical) sibling donor. Criteria for exclusion were (a) abnormal cardiac function (systolic ejection fraction o50%), (b) chronic respiratory disease, (c) abnormal liver function, (d) psychiatric disease, and (e) HBsAg-or HIV-positive test of either patient or donor. The protocol was approved by the local Bio-ethical Committee and both recipients and donors were required to sign a written informed consent before admission.
There were 30 patients: 23 males and seven females. Their ages ranged from 31 to 55 years (median 48). Their characteristics, including stage, 12 Ig class, number of chemotherapy lines prior to allograft, time from diagnosis to transplant, status at transplant, and conditioning regimen are shown in Table 1 .
Treatments prior to allograft and status at transplantation
Chemotherapy given to the patients prior to the allograft differed widely from patient to patient. It consisted of VAD 13 or a VAD-based regimen in 13 patients. A more intense debulking with VAD followed by 1-3 courses with intermediate or high-dose chemotherapy with autologous stem cell support 14 was employed in 10 patients. Two patients received multiple courses of cyclophosphamide (Cy) 1.2 g/m 2 /day for 2 days along with 40 mg dexamethasone (CyDexa) for four consecutive days. The remaining six had received different standard-dose treatments not reported here. Disease status was assessed prior to the transplant preparative regimen. Four patients were in complete remission (CR), 11 in partial remission (PR), 13 were considered to be nonresponders (NR), and two had progressive disease (PD) ( Table 1) .
Donor PBSC mobilization and collection
Stem cells were mobilized into the peripheral blood by treating the donors with hematopoietic growth factors. In total, 26 donors received subcutaneous G-CSF in two divided daily subcutaneous injections at the dose of 10 mg/ kg/day for 5 days before starting the aphereses and until the end of the collection procedures. 15 In four other donors, the schedule was of subcutaneous GM-CSF 5 mg/kg/day for 2 days, followed by G-CSF 16 mg/kg/day for 3 days or till the end of apheretic collections. Treatment was performed in all cases. A continuous (the CS-3000 'plus', Baxter Corp., Deerfield, IL, USA, or the AS-104, Fresenius AG, Bad Homburg, Germany) or a discontinuous-flow device (MCS 3p, Haemonetics Corporation, Braintree, MA, USA) was employed for mononuclear cell apheresis collection. Aphereses were regularly run on consecutive days via antecubital vein access following single-institution protocols. As a rule, cells were stored at 41C until infusion.
Transplant, conditioning and supportive care
Conditioning was a chemotherapy combination in all cases. The combination of busulfan and melphalan (busulfan 3-4 mg/kg/day, orally, days À6 to À3; melphalan 140 mg/m 2 , i.v., day -2) 16 was employed in 25 patients, thiotepa and cyclophosphamide (thiotepa 5 mg/kg, i.v., at 12 h interval for three administrations, days À5 and À4; cyclophosphamide 60 mg/kg/day, i.v., days À3 and À2) were given in three cases. The combination of busulfan and cyclophosphamide (busulfan 4 mg/kg/day, orally, days À9 to À6; cyclophosphamide 50 mg/kg/day, i.v., days À5 to À2) was used in two patients. G-CSF or GM-CSF was never given following transplantation. Patients were nursed in single sterile positive pressure or laminar airflow rooms, and received infection prophylaxis following institutional protocols. Oral trimethoprim/sulfamethoxazole was given twice weekly starting from hematopoietic reconstitution. For CMV disease prophylaxis, peripheral blood leucocytes were monitored weekly in all patients. 17 In addition, BAL was performed on approximately day +40 if peripheral blood tests were negative. CMV infection, as defined by positive antigenemia or positive culture on BAL, was preemptively treated with ganciclovir 5 mg/kg i.v. twice daily for 7 days, followed by 5 mg/kg five times per week until day +100.
GVHD prophylaxis and treatment
GVHD prophylaxis consisted of cyclosporine (CSA) and methotrexate (MTX) in all cases. In 24 patients, CsA was given intravenously (i.v.) at a dose of 2.5 mg/kg from day 2 i.v. on days +1, +3, +6, respectively). In the absence of chronic GVHD (cGVHD), CsA was gradually tapered from day +180, and stopped 4-6 weeks later. Acute GVHD (aGVHD) was treated irrespective of its severity. The treatment was always 6-methyl-prednisolone, although doses and timing were those used in single institutions.
Criteria for response
For the purposes of the present study, CR was defined as the absence of monoclonal protein on standard serum electrophoresis, and in case of BJ proteinuria, by its disappearance, along with 5% or fewer plasma cells with normal morphology in the bone marrow, and disappearance of other plasma cell tumors. A PR was defined as a decrease of 450% in the serum M-component level or BJ protein in the urine. Patients with a response less than partial were considered as resistant (no-response, NR). Primary NR was defined as resistance to primary treatment. Progression was defined as at least a 25% increase of M component over the baseline value. Relapse was defined as M-component reappearance and/or bone marrow infiltration and/or of extraskeletal MM masses in patients otherwise in CR.
Ig-gene rearrangement studies for detection of residual myeloma cells
Clonal rearrangements of the immunoglobulin heavy chain gene locus (IgH) were used as PCR markers to detect minimal residual disease (MRD). The method has been described in detail elsewhere. 18 In brief, to amplify rearranged IgH variable regions (VDJ), RNA or genomic DNA was isolated, and VDJs were amplified starting from genomic DNA or total cDNA depending on sample availability. A dose of 1 mg of DNA or 5 ml of cDNA was amplified using two sets of consensus sense primers derived from the IgH leader and framework-1 (FR1) regions, respectively, and an antisense primer derived from the 3 0 end of joining region (JH). The reaction was carried out for 33 cycles (denaturation 941C for 30s, annealing 651C for 30s and extension 721C for 30s) with a final extension of 7 min. PCR products were analyzed by electrophoresis on 2% agarose gel. Direct sequencing of amplified VDJs was performed using the Promega fmol sequencing system. Reactions were carried out in a thermocycler at 681C annealing temperature for 15 cycles. When the sequence quality did not allow a complete reading of the second and third complementarity-determining regions (CDR), DNA was reamplified with primers containing EcoRI and HindIII restriction sites, and cloned in a Bluescript SK vector (Stratagene, San Diego, CA, USA). Restriction enzyme analysis was carried out on plasmid DNAs prepared by the alkaline lysis method, and miniprep plasmid DNAs were then sequenced. The analysis of sequencing was performed using the PC-GENE software (IntelliGenetics, Inc, Mountain View, CA, USA). For detection of residual myeloma cells, BM samples were serially evaluated after allografting. RNA (1 mg) was transcribed into total cDNA and amplified using CDR2 and JH primers (in three cases 1 mg of DNA was used, because RNA was not available), 20% of the PCR product was analyzed by agarose gel electrophoresis, blotted overnight, and hybridized to CDR3 probes endlabeled with [g-32 P]ATP. To avoid false negatives, all the DNA samples failing to produce a PCR product were reamplified, and the DNA quality was tested by amplifying the sequence of p53 exon 5 or N-ras exon 2.
Results
Hematopoietic engraftment, GVHD, and overall toxicity
The graft contained a median of 9. In total, 26 patients developed aGVHD. 10 were grade I, 11 were grade II, three were grade III, and two grade IV. Overall, grades II-IV aGVHD developed in 16 (53%) of patients and grades III-IV in five (17%) of the patients at risk. aGVHD was the major cause of death in a single patient with grade IV disease. A total of 24 patients were treated for aGVHD, all with prednisolone at a dose of 1-5 mg/kg, and 21 of them (87%) responded. Chronic GVHD (cGVHD) developed in 17 out of the 24 evaluable patients (71%). It was limited in eight and extensive in nine. The most delayed episode developed in a patient with no aGVHD but who harbored residual myeloma, and who developed de novo extensive cGVHD 10 months following transplantation. Interestingly, in a few days the myeloma disease regressed, as judged by M-component disappearance, absence of marrow plasma cells and negative PCR for IgH rearrangement.
Concerning mortality, in the present study, TRM was defined as that from any cause other than disease recurrence or progression. Overall, 10 patients died 1-48 months (median 4) from transplantation, eight of them from transplant-related causes (1-5 months, median 3), including GVHD. Cumulative TRM at 100 days from transplantation was 16%. Overall, it was 30%. As reported above, aGVHD grade IV was the cause of death in a single case. Disease progression (n ¼ 1), infection (n ¼ 2), interstitial pneumonia (n ¼ 1), thrombotic thrombocytopenic purpura (n ¼ 1), hemorrhage(n ¼ 1), cardiac failure (n ¼ 1), Allogeneic PBSCT for myeloma I Majolino et al ARDS combined with grade IV aGVHD (n ¼ 1), and multiorgan failure (n ¼ 1) were reported as causes of death in the remaining patients.
Disease response
At the time of transplantation, four patients were already in CR, 11 were in PR, 13 were nonresponders, and two had PD. Of the 23 patients who still had detectable disease and were evaluable for response, 18 (78%) entered CR with transplantation. One of them had PD at the time of the allograft, and achieved CR as late as 1 year after transplantation, concurrently with the onset of cGVHD. This patient is still alive in CR, with cGVHD, at 50 months follow-up. Overall, following transplantation, 22 out of the 27 (81%) evaluable patients were in CR. Only one of the CR patients has relapsed, 32 months after transplantation. He proved resistant to subsequent salvage treatment, and died with PD 48 months from transplantation. Another patient, who was in PR after transplantation, had extraskeletal progression with the development of an intrathoracic paravertebral mass 8 months after the allograft. He was treated with DLI with no success, and later underwent surgical excision of the mass before receiving a second transplant, but died of sepsis 4 months later. Neither of these two patients had experienced aGVHD or cGVHD. Probability of relapse or progression is represented in Figure 1 .
Overall survival (OS) and event-free survival (EFS) are shown in Figure 2 . In total, 60% of patients are projected to survive 73 months from transplantation. At that time point, 67% out of the total are projected to be free from events.
Residual disease monitoring
Results of residual disease monitoring by PCR analysis of Ig-gene rearrangement are shown in Figure 3 
Bone Marrow Transplantation
Allogeneic PBSCT for myeloma I Majolino et al patients were analyzed at least once after transplantation. Two of them (#3 and 4) died too early while in molecular remission. Another patient (#8) was in PR following transplantation. He still had an extramedullary myeloma mass located intrathoracically as a paravertebral mass. Despite the mass, this patient was PCR-negative on three subsequent controls. He only became PCR-positive a year after transplantation when overt bone marrow progression ensued (see above). In another patient (#10), clinical and molecular remission paralleled the emergence of cGVHD. In fact, the patient entered CR and became PCR-negative a year after transplantation as soon as cGVHD developed (see above). Overall, six out of the 11 molecularly studied patients had at least two consecutive PCR-negative followup samples. Five also reached clinical remission. None of them has relapsed to date.
Discussion
We had previously reported preliminary results, 11 showing that, in MM, allogeneic transplantation with G-CSFmobilized PBSC is able to induce long-lasting remissions in a sizeable proportion of patients. In the present report, we confirm our observation in a larger number of patients.
MM patients are usually older than other transplant categories, and in fact in our series the median age was 48 years. It is well known that a high number of progenitors in the graft is not only able to give more rapid and stable engraftment, but is also the main factor for survival, at least in leukemia. [19] [20] [21] All our patients engrafted rapidly, and required minimal transfusion support. Nearly 50% had refractory or PD. The transplants were carried out at different times from diagnosis, in most after multiple lines of chemotherapy, and in 10 after an intensive program including one or more courses of high-dose melphalan with autologous stem cell support. 22 TRM was 30% overall, lower than in most previous single-center or registry studies. In the retrospective single-center study of Bensinger et al, 6 among the 80 patients studied, the nonrelapse mortality within the first 100 days was 44%. However, onethird were conditioned with a TBI-containing regimen, and 14 received the marrow from related mismatched or unrelated donors. Median interval from diagnosis to transplant was as long as 2 years. Bjorkstrand et al 9 made a retrospective matched-pair analysis within the EBMT, to compare results of autologous and allogeneic transplantation. At 36 months, TRM was 41% in the allogeneic group, but this study included patients transplanted between 1983 and 1994. In a retrospective analysis by Gahrton et al, 23 reduction in TRM appeared more a function of year of transplant than of stem cell source. As a consequence, improved results might be related to earlier transplantation, less prior chemotherapy, and better supportive care. In the present series however, TRM was not apparently higher in patients with a long pretransplant history, but while among the 10 patients with one or more previous high-dose treatments four (40%) died of transplant-related causes, among the remaining 20 this occurred only in five (20%). These results may be because of the limited number of patients. Nonetheless, it appears reasonable not to delay allogeneic transplantation after rapid induction chemotherapy and before cell resistance 24 and therapy-related organ damage develop. 22 At the time of the allograft, only four patients were already in CR, while the majority were in PR or had resistant-PD. Conditioning treatment was highly effective. In the majority, we used a busulfan-melphalan combination for conditioning, obtaining over 70% CR. Responses were of long duration, with a probability of PFS at over 65% at 6 years. The cause of failure was disease recurrence or progression in only two patients. Molecular analysis was available in only 11 patients, but showed the disappearance of the neoplastic clone in eight out of the 10 CR patients analyzed. It is worth noting that our criteria for response are looser than those subsequently adopted by the EBMT. 25 As GVHD prophylaxis, we adopted the standard MTX-CSA combination, and CSA was gradually tapered from day +180 in patients without cGVHD. While the incidence of aGVHD grade II-IV reached the expected 50%, with 17% grade III-IV, despite prolonged CSA administration, cGVHD incidence almost doubled that usually seen with bone marrow cells. Whether the reported increased cGVHD incidence after PBSC transplantation 26, 27 is able to prevent disease relapse in MM too cannot be ascertained on the basis of our data alone, although a number of reports point to the alloimmune response as an effective mechanism for myeloma clone suppression. [28] [29] [30] It is believed that graft-versus-myeloma (GVM) is induced by allospecific T cells, and cytotoxicity is mediated mainly by type 1, TNF, and IFN-gamma secreting CD8+ T cells. 31 T-cell clonal expansion is found in the vicinity of the myeloma cells, giving evidence for the presence of specific T-cell/tumor cell interaction in the disease. 32 PBSC may contain over one log-fold higher T-cell number, and this may influence lymphocyte recovery postgraft, and disease eradication. In a randomized study, 33 probability of relapse was significantly higher in the bone marrow group than in the PBSC group; all five relapses in fact occurred among bone marrow recipients, who also showed a higher proportion of absolute lymphopenia and CD4 lymphopenia in comparison with PBSC patients. The advantage of PBSC could become more apparent in selected diseases such as MM or chronic myelogenous leukemia. 34, 35 Our patients received a median of 2.2 Â 10 8 /kg CD3+ cells, approximately one log-fold more than bone marrow transplant patients. Accordingly, cGVHD occurred in over 60% cases. Again, the numbers are too small to investigate a correlation between ongoing remission and cGVHD. However, none of the two responding patients whose disease relapsed or progressed after transplantation had cGVHD, in comparison with 10 out of the 18 still in remission. It seems meaningful that cGVHD and CR occurred simultaneously in one patient whose disease did not respond to the conditioning regimen. He entered clinical and molecular remission only 1 year after transplant, with the development of de novo cGVHD. The key role of allogeneic T cells is strengthened by the results of donor lymphocyte infusions after failure of T-cell depleted allografts: in most cases, the response came along with GVHD emergence. 29, [36] [37] [38] [39] In the present study, we attempted to analyze the influence of the following factors on TRM, OS, and EFS: age (o49 vs X49 years), sex, Ig-class, stage, time to transplant, previous autograft, status at transplantation, number of CD34+ and CD3+ cells infused, aGVHD, and cGVHD. A significantly negative influence on TRM was found only for aGVHD (P ¼ 0.0068), which also negatively influenced OS (P ¼ 0.0047). An influence of a prior autotransplant on TRM was of borderline significance (P ¼ 0.0631). The only factor that showed a significantly positive influence on EFS was cGVHD (0.0359). These results, however, should be evaluated carefully because of the limited number of patients.
We performed the PCR analysis for MRD assessment in only a limited number of cases, as the technique requires the construction of patient disease specific probes on plasma-cell-containing samples. The method we adopted is extremely sensitive, allowing the identification of 10 À5 clonal plasma cells. Among the 11 patients studied (Figure 3 ), nine entered remission soon after transplantation, while one (#10) was the one achieving clinical and molecular remission only 1 year after the allograft with the development of de novo cGVHD, and another (#8) whose marrow showed no cytological and molecular disease had a large thoracic myeloma mass and soon relapsed. Of the nine CR patients with at least one negative PCR sample after transplantation, two soon died of transplant-related complications, while the others remained in CR. There were only two persistently PCR-positive patients: one of them relapsed (#7), and the other (#13) is still disease-free. In contrast to leukemia, MM is frequently a focal disease and analyzing a random bone marrow sample can theoretically be misleading as PCR negativity may coexist with extramedullary disease. Nonetheless, in our series, PCR negativity occurred in all persistent CR patients who were studied, suggesting that allogeneic transplantation is able to eradicate the disease serologically and molecularly. These data are in agreement with the results of a larger EBMT analysis 40 showing that 80% patients allografted with PBSC will develop PCR negativity as compared to only 45% of those allografted with bone marrow cells. In the study by Cavo et al, 41 PCR negativity was maintained for as long as 10 years, and none of the nine PCR-negative patients experienced disease relapse.
In conclusion, our data compare favorably with historical bone marrow transplantation data, and suggest that, in MM allogeneic transplantation with growth factor-primed PBSC has a high rate of remission. The 30% overall nonrelapse mortality can in part be explained by the heavy pretransplant treatments of our patients. Different conditioning approaches, however, are expected to significantly reduce mortality rates, as may the combination of highdose autologous stem cell transplantation with allogeneic graft. A total of 32 patients aged 39-71 years were treated by Maloney et al, 42 with day 100 mortality of 6%, an overall response rate of 84 and 53% CR.
In our study the patients, once they had achieved CR had a low probability of recurrence. These results are biologically confirmed by PCR assay showing profound suppression of the neoplastic clone. Again, the small number of patients in the study and the lack of data concerning pretransplant prognostic factors including b-2-microglobulin and cytogenetic abnormalities make it difficult to draw conclusions. Nevertheless, a long-lasting alloimmune control of tumor regrowth could be the basis of clinical remission in this disease. Whether this is the case and for how long this mechanism could succeed in preventing disease recurrence is presently unknown.
